While these approaches have shown great potential for delineating claudin-4 expression in tumour tissue and precancerous lesions in vivo, CPE-based imaging agents suffer from poor solubility, unknown immunogenicity and exhibit only moderate affinity and specificity for claudin-4. The gene discussed is CLDN4; the disease is neoplasm.